{
    "nct_id": "NCT00042172",
    "title": "Cognitive Enhancers Explored With PET Imaging",
    "status": "COMPLETED",
    "last_update_time": "2014-02-27",
    "description_brief": "The purpose of this study is to evaluate the effectiveness of donepezil (Aricept) for the treatment of mild cognitive impairment (MCI) in elderly adults. This study will also determine whether adding ginkgo biloba extract (GBE) enhances the effects of donepezil.",
    "description_detailed": "Cognition involves important thinking processes such as perception, learning, and reasoning. There are currently no definitive treatments for cognitive deterioration. This study focuses on elderly individuals with MCI because people at a pre-dementia stage may sustain the greatest and most lasting benefit from cognitive-enhancing agents.\n\nPatients receive either donepezil or placebo for the first 6 months of the study. In the second 6 months of the study, patients are randomized to receive either donepezil plus GBE or donepezil alone. Positron Emission Tomography (PET), which provides a color-coded image of the brain's blood flow in a particular area, is used to assess brain activity during memory tasks. A PET scan is performed at study entry, 6 months, and 1 year. A vasodilator (a drug that dilates the blood vessels) is administered during the PET imaging procedure to determine whether vascular disease affects memory function. A magnetic resonance imaging (MRI) scan is also taken to view the brain.",
    "phase": [
        "PHASE4"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "donepezil (Aricept) \u2014 small-molecule acetylcholinesterase inhibitor (symptomatic cognitive enhancer)",
        "ginkgo biloba extract (GBE) \u2014 herbal extract / cognitive-enhancer adjunct"
    ],
    "placebo": [
        "placebo (used in trial control arm)"
    ],
    "explanation_target": [
        "Reason: The trial tests donepezil (a cholinesterase inhibitor that increases synaptic acetylcholine and is used to improve cognition symptomatically) and whether adding ginkgo biloba extract enhances donepezil's effects; the primary intent is to improve cognition in MCI rather than to target core AD pathology (amyloid/tau). \ue200cite\ue202turn1search1\ue202turn2search10\ue201",
        "Act: Key trial details \u2014 title \"Cognitive Enhancers Explored With PET Imaging\" (NCT00042172), interventions are donepezil and GBE with placebo-controlled phases; PET/MRI were used for imaging assessments but the intervention is pharmacologic. This identifies the interventions as cognitive enhancers rather than disease-modifying biologics/small molecules targeting amyloid or tau. \ue200cite\ue202turn1search1\ue202turn1search4\ue201",
        "Act (mechanisms / drug target): Donepezil is a centrally acting, reversible acetylcholinesterase inhibitor (small molecule) \u2014 its target is acetylcholinesterase and its effect is symptomatic cholinergic enhancement rather than direct modification of amyloid/tau pathology. Ginkgo biloba extract is a standardized herbal extract proposed to have antioxidant, platelet-activating-factor antagonism, and neuromodulatory (including cholinergic) effects and is used here as a cognitive-enhancing adjunct. \ue200cite\ue202turn2search10\ue202turn2search1\ue201",
        "Reflect: Classification check \u2014 per the provided category definitions, donepezil (small-molecule AChE inhibitor used to improve cognition) and GBE (cognitive enhancer adjunct) best fit the \"cognitive enhancer\" category. They are not biologic monoclonal antibodies nor small molecules described as disease-modifying anti-amyloid/tau agents, and the trial's aim is symptomatic cognitive improvement in MCI, so 'cognitive enhancer' is the correct classification. \ue200cite\ue202turn1search1\ue202turn2search7\ue201",
        "Web search results (sources used): Clinical trial summary / registry for NCT00042172 showing title, purpose, interventions, PET use and design. \ue200cite\ue202turn1search1\ue202turn0search4\ue201",
        "Donepezil mechanism and clinical role (AChE inhibitor; symptomatic cognitive enhancer, not proven disease-modifying). \ue200cite\ue202turn2search10\ue202turn2search7\ue201",
        "Ginkgo biloba extract: review summaries describing antioxidant, platelet-activating factor antagonism, and cholinergic-modulatory actions; used as a cognitive enhancer adjunct. \ue200cite\ue202turn2search1\ue202turn2search0\ue201",
        "Notes / ambiguity: The trial includes PET imaging as an outcome/assay (title and description), but that is an imaging/biomarker component of the study \u2014 it does not change the trial\u2019s therapeutic intent. If you want, I can fetch the full ClinicalTrials.gov record text or any publications/results linked to NCT00042172 for more detail. \ue200cite\ue202turn1search1\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests donepezil (a centrally acting, reversible acetylcholinesterase inhibitor that increases synaptic acetylcholine to improve cognition symptomatically) and ginkgo biloba extract (a multi-component herbal extract with proposed cholinergic-modulatory, antioxidant and platelet-activating-factor\u2013antagonist actions). The interventions are intended as symptomatic cognitive enhancers in MCI rather than disease-modifying anti-amyloid or anti-tau agents, so the primary biological focus is modulation of neurotransmission/cholinergic function. \ue200cite\ue202turn0search6\ue202turn1search2\ue202turn0search1\ue201",
        "Act: Key extracted details \u2014 interventions: donepezil (Aricept; acetylcholinesterase inhibitor) and Ginkgo biloba extract (GBE) used as an adjunct; trial title/registry: 'Cognitive Enhancers Explored With PET Imaging' (NCT00042172). Donepezil\u2019s mechanism (AChE inhibition \u2192 increased acetylcholine at synapses) directly targets cholinergic neurotransmission; GBE is included for potential neuromodulatory/antioxidant adjunct effects. These map best to CADRO category D (Neurotransmitter Receptors / modulation of neurotransmitter systems) because the trial\u2019s mechanism is cholinergic enhancement rather than targeting amyloid, tau, inflammation, or vascular pathology. \ue200cite\ue202turn1search2\ue202turn1search0\ue202turn0search3\ue201",
        "Reflect: The classification as D) Neurotransmitter Receptors fits the description: donepezil is a symptomatic cholinergic enhancer (not disease-modifying) and GBE is used as a cognitive-enhancing adjunct with cholinergic and antioxidant actions. Although GBE has antioxidant and PAF-antagonist properties (which could overlap with oxidative stress or vascular categories), the trial\u2019s explicit intent is symptomatic cognitive enhancement via cholinergic modulation, so a neurotransmitter/neurotransmission category (D) is the most specific CADRO match. PET/MRI use in the study is an imaging/biomarker component and does not change the therapeutic target classification. \ue200cite\ue202turn0search1\ue202turn0search4\ue202turn1search2\ue201",
        "Web search results / sources used: ClinicalTrials.gov summary for NCT00042172 (trial title, interventions, PET/MRI imaging and design). \ue200cite\ue202turn1search2\ue201",
        "Donepezil mechanism and prescribing information (Aricept label; donepezil = reversible acetylcholinesterase inhibitor; symptomatic cognitive enhancer in AD). \ue200cite\ue202turn1search0\ue202turn0search6\ue201",
        "Ginkgo biloba extract reviews describing PAF-antagonism, antioxidant/free-radical scavenging, and cholinergic-modulatory effects; NCCIH summary on ginkgo and cognitive function (no conclusive evidence for dementia prevention, but mechanistic and clinical literature on cognitive effects). \ue200cite\ue202turn0search1\ue202turn0search3\ue202turn0search4\ue201",
        "Notes/ambiguity: Ginkgo\u2019s multiple mechanisms could also overlap with CADRO categories G) Oxidative Stress or K) Vasculature (via PAF/vascular effects), but the trial\u2019s primary therapeutic intent (symptomatic cholinergic cognitive enhancement) supports assigning the neurotransmission category rather than switching to multi-target (R). If you prefer an alternative mapping emphasizing antioxidant/vascular mechanisms for GBE, I can re-evaluate and assign R) Multi-target or G/K accordingly."
    ]
}